Sales and marketing expenses were $34.4 million for the year ended June 30, 2026, an increase of $6.1 million, or 21.8%, compared to $28.2 million for the year ended June 30, 2025, primarily due to increased headcount and wage rates, and increased marketing spend to support growth.

filing / Sep 9, 2026 / receipt

The increase was primarily due to (i) $2.7 million net increase in employee compensation and benefits as the result of organizational restructure, executive severance, and an increase in headcount and wage rates, partially offset by lower variable compensation associated with the restructure, (ii) $2.4 million increase in consulting services, (iii) $0.9 million increase in software license fees, and (iv) a $36.8 mill

filing / Sep 9, 2026 / receipt

While providers, payors, and technology companies have made significant investments in solutions designed to improve quality and reduce costs, the healthcare industry remains in a multi-year transition toward value-based reimbursement, with traditional fee-for-service payment arrangements continuing to represent a meaningful portion of healthcare spending.

filing / Sep 9, 2026 / receipt

Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures were effective as of June 30, 2026.

filing / Sep 9, 2026 / receipt

Furthermore, the administration has reshaped the Center for Medicare and Medicaid Innovation (CMMI) to focus on cost reduction strategies and program integrity initiatives, such as the CMS “Comprehensive Regulations to Uncover Suspicious Healthcare” (CRUSH) initiative launched in 2026.

filing / Sep 9, 2026 / receipt

Sales and marketing expenses were $24.4 million for the nine months ended March 31, 2026, an increase of $3.3 million, or 15.7%, compared to $21.1 million for the nine months ended March 31, 2025 primarily due to increased headcount, wage rates, and marketing spend to support growth.

filing / May 8, 2026 / receipt

Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of March 31, 2026.

filing / May 8, 2026 / receipt

to the nine months ended March 31, 2025 was primarily due to (i) $1.5 million net increase in employee compensation and benefits as the result of organizational restructure and executive severance and an increase in headcount and wage rates, partially offset by lower variable compensation associated with the restructure (ii) $0.5 million increase in contract services, (iii) $1.0 million increase in software license f

filing / May 8, 2026 / receipt